Kintor Pharmaceutical Ltd(KNTPF)

Description: Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; and GT1708F, for the treatment of leukaemia and basal-cell carcinoma. The company was founded in 2009 and is headquartered in Suzhou, China.

---

Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Oncology Breast Cancer Prostate Cancer Antineoplastic Drugs Liver Cancer Treatment Of Various Cancers Acne Vulgaris Androgenetic Alopecia Metastasis Basal Cell Carcinoma Metastatic Castration Resistant Prostate Cancer Anti Acne Preparations Anaplastic Lymphoma Kinase Mtor Inhibitors Antiandrogen Leukaemia Metastatic Hepatocellular Carcinoma Metastatic Solid Tumours

---

Home Page: www.kintor.com.cn

Suzhou Industrial Park
Suzhou, 215123
China
Phone: 86 51 2626 39909

---

Officers

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)